Irinotecan Hydrochloride Trihydrate Sun (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate is employed in colorectal cancer management, targeting tumor growth and spread.

• Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine chemotherapy.
• Adjuvant treatment of colon cancer: reduces risk of disease recurrence after surgical resection.
• Advanced colorectal adenocarcinoma: provides tumor control in patients unsuitable for surgery.

• Irinotecan Hydrochloride Trihydrate is a pro‑drug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the topoisomerase‑DNA cleavable complex, it prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage, replication arrest, and ultimately apoptotic cell death in rapidly dividing tumor cells.

Irinotecan Hydrochloride Trihydrate may cause a range of adverse reactions, some of which are expected with cytotoxic chemotherapy.

Common Side Effects

• Nausea and vomiting: may require anti‑emetic therapy.
• Diarrhea: can be severe and may need antidiarrheal agents.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: temporary hair loss.
• Fatigue: generalized tiredness.
• Mild hepatic enzyme elevation.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils, requiring urgent care.
• Severe colitis or ileitis: potentially life‑threatening bowel inflammation.
• Hepatic toxicity: marked liver enzyme rise or jaundice.
• Anaphylactic reactions: rare but may be severe.
• Severe hypotension: sudden drop in blood pressure during infusion.
• Secondary malignancies: rare long‑term risk associated with alkylating agents.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for toxicity.

• Monitor blood counts: perform regular CBC to detect neutropenia.
• Assess liver function: adjust dosing in hepatic impairment.
• Avoid in pregnancy: contraindicated due to fetal risk (Category D).
• Use anti‑emetics: manage nausea and vomiting proactively.
• Maintain hydration: ensure adequate fluid intake to reduce diarrhoea severity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan Hydrochloride Trihydrate can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: increase irinotecan exposure and toxicity.
• UGT1A1 inhibitors (e.g., atazanavir): raise SN‑38 levels, heightening risk of neutropenia.
• Concurrent myelosuppressive agents: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may enhance bleeding risk.
• Live vaccines: immunosuppression can reduce vaccine efficacy.
• Diuretics: potential electrolyte disturbances during fluid loss.
• Proton‑pump inhibitors: may affect gastric pH but limited impact on IV administration.